| |
The scientific community universally recognizes peer-reviewed literature as the foundation of credible and reproducible research. However, its exponential growth presents a significant challenge for R&D teams in biotech and pharma companies. Learn how to leverage AI to ensure that today’s advancements in drug discovery, clinical trials and regulatory processes are based on data that is up-to-date, validated and meaningful. Download now. 
|
|
Today’s Big NewsJul 17, 2025 |
|
Thursday, July 22, 2025 | 10am ET / 7am PT Join us to take an exciting look at the forefront of REMS transformation. Learn how leading technology, integrated strategies and operational excellence are redefining what’s possible. Gain the insights you need to reduce complexity, enhance compliance and deliver more value across the REMS lifecycle. Register now. 
|
|
| By Zoey Becker Members of the FDA's Oncologic Drugs Advisory Committee voiced concerns with ocular toxicity side effects, proposed dosing and a lack of diversity in GSK's trial program. |
|
|
|
By Darren Incorvaia As measles cases surge to record levels in the U.S., Department of Health and Human Services Secretary Robert F. Kennedy Jr. has downplayed the effectiveness of the long-used vaccine and instead promoted the development of new treatments for the virus. |
By Andrea Park After a nine-month investigation into direct-to-consumer telehealth platforms launched by Eli Lilly and Pfizer, a group of senators has released a report suggesting the platforms may allow pharmas to inappropriately influence doctors’ prescribing habits. |
By Kevin Dunleavy Taking a page from Eli Lilly and Novo Nordisk, who have launched online programs to sell their diabetes and obesity drugs directly to patients, Bristol Myers Squibb and Pfizer are doing the same with their mega-blockbuster blood thinner Eliquis. |
|
Wednesday, July 23, 2025 | 2pm ET / 11am PT The development of radiopharmaceuticals is transforming oncology. Designing successful clinical trials in this space, requires a precise balance of insight, efficiency, and strategy. Join our expert panel to explore the imaging strategies, trial design principles, and regulatory alignment considerations you need to know about. Register now. 
|
|
By Gabrielle Masson Sarepta Therapeutics has laid off 500 staffers, or 36% of its workforce, as part of a strategic restructuring aiming to save $400 million annually. |
By Angus Liu Novartis is launching a $10 billion share buyback to be completed by year-end 2027 as new drug launches accelerate. |
By Gabrielle Masson The U.K. is establishing a new biosecurity center designed to improve research into potentially pandemic-causing pathogens and protect against emerging public health threats. |
By Conor Hale CEO Robert Ford said sales of its Navitor TAVR implant have doubled over the past two years, and that the road ahead looks favorable. |
By Nick Paul Taylor Leo Pharma’s inaccurate Innohep app has prompted a slap-down from the PMCPA. The U.K. marketing watchdog ruled Leo brought discredit on the pharma industry by leaving the app live for three months after the errors were discovered. |
By Fraiser Kansteiner Pfizer’s multi-year effort to stabilize its U.S. penicillin supply has hit an unexpected hitch after particulate concerns prompted a recall of the company’s long-acting injectable form of the ubiquitous antibiotic. |
By Zoey Becker Define Ventures' report on the industry's approach to AI found that 85% of Big Pharma leaders consider AI an "immediate priority," with 85% planning to increase their AI budgets in turn. |
By Conor Hale The company said two surgeons, 4,000 miles apart, handed off control of a single da Vinci 5 system in real-time during the Society of Robotic Surgery conference in France. |
By Nick Paul Taylor BioNTech is losing its chief strategy officer, with Ryan Richardson set to leave the company at the end of September to "pursue new professional opportunities." |
Fierce podcasts Don’t miss an episode |
| Biopharma layoffs have held steady through mid-2025, and in this episode of "The Top Line," we dig into the numbers, closures and policy changes shaping the trend. |
|
|---|
|
|
|
QPS delivers global RWE solutions to support regulatory and drug development goals. With access to diverse data sources and deep regulatory expertise, QPS transforms real-world data into actionable insights. +(2)+(2)+(1)+(1)+(1).png)
|
|
Whitepaper This white paper outlines how we apply industry-backed practices and proprietary technologies to proactively safeguard sterility and performance. Sponsored by: Lonza |
Whitepaper Presented by Blue Matter, strategic consultants in the life sciences Sponsored by Blue Matter Consulting |
| Sheraton Philadelphia Downtown |
|
| The Lighthouse at Pier 61 in New York City |
|
|
| |
|
